Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
Clinical trial NCT04179084 · UNKNOWN
Trial details
- NCT number
- NCT04179084
- Sponsor
- Chinese PLA General Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-28
- Primary completion
- 2020-03-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.